May Hughes (hoerepair26)

Pericardial neoplasms are uncommon, mostly due to secondary involvement of the pericardium by extracardiac tumors. Clinical presentation is nonspecific, frequently leading to a delayed diagnosis. Moreover, both benign and malignant pericardial tumors may be associated with myocardial infiltration and mechanical compression of cardiac chambers, possibly precipitating clinical conditions. Pericardial tumors are indeed a diagnostic and therapeutic clinical challenge. This review aims to provide an overview of the main clinical characteristics of pericardial tumors, along with their management in clinical practice. Multimodality imaging (echocardiography, chest X-ray, CT, CMR, and PET) enable full characterization of pericardial neoplasms. An individualized strategy should be developed by a multidisciplinary team including cardiologists, oncologists, radiologists, and cardiac surgeons. Multimodality imaging (echocardiography, chest X-ray, CT, CMR, and PET) enable full characterization of pericardial neoplasms. An individualized strategy should be developed by a multidisciplinary team including cardiologists, oncologists, radiologists, and cardiac surgeons. We evaluated the efficacy and safety of dalbavancin in ABSSSI and 'other sites' infections' (OTA). Observational study involving 11 Italian hospitals including patients that received ≥1 dose of dalbavancin in 2016-2019. Epacadostat The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in a real-life setting. 206 patients enrolled (males 50%, median age 62 [IQR 50-76] years), 60.2% ABSSSI, 39.8% OTA. 69.7% ABSSSI 90.7% OTA (p=0.003) and 46.3% ABSSSI 37.2% OTA (p=0.786) received previous and concomitant antibiotics, respectively. 82.5% reached clinical cure . Eleven (5.4%) patients had non-serious adverse events (AE). OTA patients showed longer hospitalization (13.5days, 5.5-22 3, 0-11.7; p<0.0001) and received longer previous (18days, 9-30 11, 7-19; p =0.007)/concomitant antibiotic treatments (21days, 14-52 11, 8-14; p <0.0001), compared to ABSSSI. ABSSSI and OTA showed similar efficacy (85.5% 75%, p =0.459) and safety (no AE 81.5% 64.3%, p =0.258); efficacy was independent of previous/concomitant therapies. Dalbavancin demonstrated a success rate of >80%, with similar efficacy/safety in ABSSSI and off-label indications. The preferential use of dalbavancin as second-line or combination therapy would seem to suggest the need for in-depth studies focused on its off-label use. 80%, with similar efficacy/safety in ABSSSI and off-label indications. The preferential use of dalbavancin as second-line or combination therapy would seem to suggest the need for in-depth studies focused on its off-label use.The terms, institutional and scientific, integrity appeared in the literature 986 times from 2005 to 2015. How has the term integrity, with its dual definition, a) The accuracy, completeness and consistency of data and b) the adherence to a code of moral values, been applied to an institution? The authors suggest that a post hoc inquiry be instituted following the finding of an individual act of research misconduct to determine if the sponsoring institution, actively or passively, played a contributory role and if corrective action was taken. This would serve as one measure of institutional integrity.Microplastics (MPs) are unavoidably ingested by humans, and their gastrointestinal processes and impact on lipid digestion are unknown. In the present work, all five MP types used, including polystyrene (PS), polyethylene terephthalate, polyethylene, polyvinyl chloride, and poly(lactic-co-glycolic acid) (80 mg/L in small intestine), significantly reduced lipid digestion in the in vitro gastrointestinal system. PS MPs exhibited the highest inhibition (12.7%) among the five MPs. Lipid digestion decreased with increasing PS concentration, but